Read, understand and consent to the blog's DISCLAIMER here before proceeding to read the article
http://www.scribd.com/doc/99941501/13272520-4 Interview Summary
It is now somewhat clear what they are trying to do in the Anchor patent where they received final rejection in March. Strong arguments on differentiation from prior art.
It also appears the claims can only prevent generics from marketing AMR101 for the indication if they are already on stable statin therapy. Still very valuable
See the "Campostar label case" where it was ruled generics could carve out specific labels -> Campostar case
see the core claims 12 and 24.